Physician profile
Kadijah Jones
NPI 1518988294
$1,989.87
in general payments reported to CMS, 2019-2025
27 companies · $348 in 2025
The $348 reported for 2025 was more than what 78% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $189 · 2021: $284 · 2022: $97.76 · 2023: $367 · 2024: $312 · 2025: $348.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,013 · Entertainment: $14.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,013.11 |
| Entertainment | $14.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $312.19 | 2019-2025 | Wegovy |
| Pfizer INC. | $290.99 | 2019-2025 | |
| Lilly USA, LLC | $212.50 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $194.99 | 2022-2025 | |
| Cvrx, INC. | $136.53 | 2023 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $115.12 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Astrazeneca Pharmaceuticals LP | $112.13 | 2019-2021 | |
| Abbott Laboratories | $75.14 | 2019-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $73.89 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.80 | 2021-2022 | |
| Dexcom, INC. | $43.27 | 2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $37.45 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $35.52 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.88 | 2020 | |
| Hologic Sales and Service, LLC | $29.67 | 2024 | Aptima, Thinprep 2000 Processor |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $27.84 | 2020-2021 | |
| Phadia US INC. | $26.10 | 2019-2023 | Immunocap |
| Organon LLC | $22.32 | 2024 | |
| Seqirus USA INC | $20.61 | 2025 | Fluad, Flucelvax |
| Sanofi Pasteur INC. | $19.72 | 2024 | |
| Alexion Pharmaceuticals, INC. | $19.03 | 2025 | Strensiq |
| Abiomed | $18.91 | 2025 | |
| Amarin Pharma, INC. | $17.46 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.63 | 2019 | |
| Esperion Therapeutics, INC. | $14.75 | 2020 | |
| Amgen INC. | $14.23 | 2025 | Otezla, Repatha |
| Optos, INC. | $14.20 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kadijah Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.